CIRM Funded Clinical Trials

A Phase 1 study of an engineered Treg cell therapy, GNTI-122, in adults with recently diagnosed Type 1 Diabetes

Disease Area:

Type 1 diabetes

Investigator:

Institution:

CIRM Grant:

CLIN2-20416 (Pre-Active)

Award Value:

$7,766,382.00

Trial Sponsor:

GentiBio

Trial Stage:

Phase 1/2

Trial Status:

Launching

Targeted Enrollment:

N/A